

Res. Asst. BURAK YASİN AKTAŞ

Personal Information

Email: byaktas@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/byaktas>

International Researcher IDs

ORCID: 0000-0001-5460-4895

ScopusID: 57207692951

Yoksis Researcher ID: 165424

Education Information

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2017 - Continues

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2012 - 2016

Undergraduate, Hacettepe University, Tıp Fakültesi, Turkey 2004 - 2010

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)**
YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)
- II. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpinar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.
Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)
- III. **Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?**
GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., ERMAN M., Yumuk P. F., Şenler F. Ç., Çakar B., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.14, pp.13271-13277, 2023 (SCI-Expanded)
- IV. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.
INTERNATIONAL JOURNAL OF CANCER, vol.152, pp.679-685, 2023 (SCI-Expanded)
- V. **Emerging treatment strategies in hepatobiliary cancer**
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN S., DİZDAR Ö.
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)
- VI. **Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics**
Ozer O., NEMUTLU E., REÇBER T., Eylem C. C., AKTAŞ B. Y., KIR S., Kars A., AKSOY S.

- EUROPEAN JOURNAL OF MASS SPECTROMETRY, vol.28, no.1-2, pp.56-64, 2022 (SCI-Expanded)
- VII. **Pazopanib-induced chylothorax in a patient with renal cell carcinoma**
 KÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D.
 ANTI-CANCER DRUGS, vol.33, no.1, 2022 (SCI-Expanded)
- VIII. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**
 Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.
 FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- IX. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**
 GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.
 BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)
- X. **Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study**
 Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., BAŞOĞLU TÜYLÜ T., İlhan A., Akdeniz N., Gulmez A., et al.
 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded)
- XI. **The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).**
 Bilgetekin I., Dogan M., Karacin C., Basal F. B., Esin E., Ucar G., Isak O. A., Imamoglu G. I., Keskin G. S. Y., Erturk I., et al.
 JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XII. **Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis**
 Akbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., Soylemezoglu F., ÜNER A., ÖZCAN M., Turker A., et al.
 LABORATORY INVESTIGATION, vol.101, pp.796-797, 2021 (SCI-Expanded)
- XIII. **Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis**
 Akbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., Soylemezoglu F., ÜNER A., ÖZCAN M., Turker A., et al.
 MODERN PATHOLOGY, vol.34, pp.796-797, 2021 (SCI-Expanded)
- XIV. **Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience**
 Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., TABAN H., GÜVEN D. C., KERTMEN N., Oksuzoglu B., et al.
 CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XV. **Cancer incidence in Behcet's disease**
 GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEM B., AKTAŞ B. Y., KIRAZ S., Gullu I., KARADAĞ Ö., DİZDAR Ö.
 IRISH JOURNAL OF MEDICAL SCIENCE, vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded)
- XVI. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**
 GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
 CLINICAL COLORECTAL CANCER, vol.19, no.3, 2020 (SCI-Expanded)
- XVII. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.**
 Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., Goksu S. S., Coskun H. S., Oyan B., Sonmez O., et al.
 JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded)
- XVIII. **Cancer incidence in Behcet's Disease.**
 Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., Gullu I. H., Karadag O., Dizdar O.

- JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded)
- XIX. **Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications**
 GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.
 FUTURE ONCOLOGY, vol.16, no.9, pp.497-506, 2020 (SCI-Expanded)
- XX. **Complete responses to two different anti-PD1 agents in a metastatic melanoma patient**
 KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
 JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.496-499, 2020 (SCI-Expanded)
- XXI. **Vitamin D Supplementation and Prevention of Type 2 Diabetes**
 AKTAŞ B. Y., Aktas O. O.
 NEW ENGLAND JOURNAL OF MEDICINE, vol.381, no.18, pp.1784, 2019 (SCI-Expanded)
- XXII. **Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy**
 AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.
 EXPERT REVIEW OF ANTICANCER THERAPY, vol.19, no.7, pp.589-601, 2019 (SCI-Expanded)
- XXIII. **Successful Treatment of Amyloid A-Type Amyloidosis Due to Behcet Disease With Tocilizumab**
 İLBAY A., ERDEN A., SARI A., ARMAĞAN B., AKTAŞ B. Y., BÖLEK E. Ç., KALYONCU U., KARADAĞ Ö.
 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, vol.25, no.4, 2019 (SCI-Expanded)
- XXIV. **Evaluation of cancer risk in patients with periodontal diseases**
 Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., Baspinar B., Akbiyik I., AKTAŞ B. Y., YÜCE D., et al.
 TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.3, pp.826-831, 2019 (SCI-Expanded)
- XXV. **Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa).**
 SUNGUR T., ASLIM B., Karaaslan C., AKTAS B. Y.
 Anaerobe, vol.47, pp.137-144, 2017 (SCI-Expanded)
- XXVI. **Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center**
 ŞENER Y. Z., AKTAŞ B. Y., Erden A., KILIÇ L., Armagan B., İNKAYA A. Ç., KARADAĞ Ö., Bilgen S. A., KİRAZ S.
 ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)
- XXVII. **Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results**
 KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., ŞENER Y. Z., KARADAĞ Ö., Bilgen S. A., AKDOĞAN A., et al.
 ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)

Articles Published in Other Journals

- I. **Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience**
 DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., Karakas Y., Kilickap S., Kars A., Turker A., et al.
 SOUTH ASIAN JOURNAL OF CANCER, vol.11, pp.287-292, 2022 (ESCI)
- II. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
 YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
 EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- III. **Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?**
 Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., MUTAŞKUN M., ERMAN M., Soylemezoglu F., Zorlu F., et al.
 CUREUS, vol.13, no.6, 2021 (ESCI)
- IV. **Mortality Facts in Internal Medicine Wards: A Descriptive Study from a University Hospital**

ÇALIK BAŞARAN N., AKTAŞ B. Y., ŞENER Y. Z., CEYLAN S., YEKEDÜZ E., BAŞPINAR B., ŞİMŞEK C., ÖZİŞIK L., SAİN GÜVEN G., ÖZ Ş. G., et al.

Acta Medica, vol.49, no.4, pp.6-13, 2018 (Peer-Reviewed Journal)

V. **Kliniko-patolojik olgu tartıflaması:Sistemik lupus eritematosus**

AKTAŞ B. Y., KALYONCU U., İNKAYA A. Ç., TUNCER M. A., ARSAVA E. M., KARLI OĞUZ H. K.

RAED dergisi, vol.6, no.1, pp.36-41, 2014 (Peer-Reviewed Journal)

Books & Book Chapters

I. **PATOFİZYOLOJİNİN TEMELLERİ**

DURUSU TANRİÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., YAVUZ SARI S. Ö., YEKEDÜZ E., GÜRLER F., KORKMAZ E. T., et al.

PALME YAYINCILIK, 2017

Refereed Congress / Symposium Publications in Proceedings

I. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30

II. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., Duran Z. C., AKIN Ş., ARIK Z., KERTMEN N., et al. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30

III. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., Kilickap S., Kars A., Turker A., Yalcin S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37

IV. **Metastatic Choroidal Melanoma: Single Center Experience**

AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., KILIÇKAP S., ÇELİK İ.

2. Ulusal Immunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48

V. **Evaluation of cancer risk in patients with periodontal diseases.**

GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., Baspinar B., AKBIYIK I., AKTAŞ B. Y., YÜCE D., et al.

2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571

VI. **TÜRKİYE'DE METASTATİK MEME KANSERİNDE HER2 HEDEFLİTEDAVİDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLİLİKLERİ**

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., OLGUN P., ŞAKALAR T., AKTAŞ B. Y., DEĞİRMENCİOĞLU S., et al.

7. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 24 March 2018

VII. **Retrospektive investigation of sepsis related inpatient mortality**

AKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., ÖZTÜRK AKTAŞ ö., ÖZİŞIK L., DURUSU TANRİÖVER M., SAİN GÜVEN G., ÖZ Ş. G.

16th European Congress of Internal Medicine, 31 August - 02 September 2017

VIII. **Retrospective Investigation of sepsis related inpatient mortality**

AKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., öztürk aktaş ö., ÖZİŞIK L., DURUSU TANRİÖVER M., SAİN GÜVEN G., ÖZ Ş. G.

ECIM, 31 August - 02 September 2017

IX. **Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program**

AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., HAYRAN K. M., ÇELİK İ.

7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017

Metrics

Publication: 43

Citation (WoS): 74

Citation (Scopus): 112

H-Index (WoS): 4

H-Index (Scopus): 5